The present study sought to determine, in more detail, the effects of an unselective and a selective adenosine A 2A 
Introduction
Adenosine is an endogenous neuromodulator acting on four different G-protein-coupled receptor subtypes: A 1 , A 2A , A 2B and A 3 (Fredholm et al., 1994) . In the basal ganglia, a group of interconnected forebrain nuclei, neuromodulation by adenosine plays a crucial role in motor control (Ferre Â et al., 1997) . In the caudate-putamen (CPu), the major input structure of the basal ganglia, A 2A receptors are selectively expressed and colocalized with dopamine D 2 receptors in a subpopulation of neurons projecting to the globus pallidus (Schiffmann et al., 1991; Fink et al., 1992) . These striatopallidal neurons constitute the indirect pathway, one of two major output pathways of the CPu controlling the activity of basal ganglia output nuclei, i.e. the substantia nigra pars reticulata and the entopeduncular nucleus. In contrast, striatonigral and striatoentopeduncular neurons regulated by A 1 receptors and D 1 receptors (Ferre Â et al., 1997) constitute the direct basal ganglia pathway. The direct and the indirect pathway have opposing effects on motor activity (Albin et al., 1989) .
Systemic blockade of A 2A receptors stimulated D 1 and D 2 receptordependent contralateral rotations in 6-hydroxydopamine lesioned rats (Pinna et al., 1996; Pollack & Fink, 1996; Fenu et al., 1997) . Furthermore, systemic administration of A 2A receptor antagonists reversed catalepsy induced by a dopamine receptor blockade or dopamine depletion and potentiated the anticataleptic effects of L-DOPA Kanda et al., 1994; Kanda et al., 1998; Shiozaki et al., 1999) . The synergistic or antagonistic motor effects mediated by A 2A and D 2 receptor ligands could be explained by direct A 2A ±D 2 receptor interactions on striatopallidal neurons (Ferre Â et al., 1997) . In contrast, interactions between the direct and the indirect pathway might account for synergistic or antagonistic motor effects of A 2A and D 1 receptor ligands (Pinna et al., 1996; Ferre Â et al., 1997) as the respective receptors are located on separate populations of striatal neurons. Recent behavioural data suggest that A 2A ±D 1 receptor interactions might not be as strong as A 2A ±D 2 receptor interactions (Pinna et al., 1996; Pollack & Fink, 1996; Fenu et al., 1997; Stromberg et al. 2000) .
In the present study, we analysed in more detail the effects of an unselective and a selective A 2A 
Materials and methods
Experiments were performed according to the current German Law on Animal Protection and were approved by the proper authorities in Stuttgart, Germany.
Animals
Male Sprague±Dawley rats (Charles-River, Sulzfeld, Germany) weighing 220±250 g on arrival were housed in groups of up to four animals in transparent plastic cages (Type IV; 35 Q 55 Q 10 cm; Ebeco, Castrop-Rauxel, Germany). In the animal house, temperature (20 T 2°C) and humidity (50 T 10%) were kept constant and a 12 h light : 12 h dark schedule was used with lights on between 06.00 h and 18.00 h. All rats were given ad libitum access to water. Standard laboratory maintenance chow (Altromin, Lage, Germany) was restricted to 15 g per animal and day. Experiments were carried out between 09.00 and 16.00 h.
Surgery
For stereotaxic surgery, animals were anaesthetized with sodium pentobarbital (50 mg/kg, i.p.; Sigma-Aldrich, Steelze, Germany) following pretreatment with atropine sulphate (0.05 mg/kg, i.p.; Research Biochemicals Int., Koeln, Germany) and secured in a Kopf stereotaxic apparatus (Kopf Instruments, Tujunga, CA, USA). Bilateral stainless steel cannulae with an outer diameter of 0.8 mm were aimed at the CPu and implanted using standard stereotaxic procedures. The co-ordinates with reference to the atlas of Paxinos & Watson (1986) (toothbar 3.3 mm below the interaural line) were: anteroposterior, 1.7 mm; anterior, bregma; mediolateral, 2.0 mm; dorsoventral, ±5.0 mm below the skull. Each rat was given at least 7 days to recover from surgery before catalepsy testing.
Drugs
For systemic administration, SCH23390 [R(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin hydrochloride] and theophylline (2,6-dihydroxy-1,3-dimethyl-purine) (Research Biochemicals Int., Koeln, Germany) were dissolved in 0.9% saline, raclopride [S(-)3,5-dichloro-N-(1-ethyl-2-pyrrolidinylmethyl)-2-hydroxy-6-methoxy-benz-amid(+)tartrate] (Astra Arcus, Soedertaelje, Sweden) was dissolved in distilled water. 8-(3-chlorostyryl)caffeine (CSC) (Research Biochemicals Int., Koeln, Germany) was suspended in 0.5% methylcellulose (Fluka, Buchs, Switzerland) . Drugs were administered intraperitoneally (i.p.) in a volume of 1 mL/kg. CSC (5 mg/kg) was administered 45 min, SCH23390 (0.75 mg/kg) and raclopride (1.25 mg/kg) 30 min, theophylline (5, 10 mg/kg) 10 min before the onset of behavioural testing; the doses and the timing of injections were chosen to ensure a pronounced drug-induced motor effect (Anderson et al., 1995; Hauber & Mu Ènkle, 1996; Kafka & Corbett, 1996) . The doses of raclopride and SCH23390 were also chosen based on their ability to induce comparable degrees of catalepsy. Administration of respective vehicles in the same volume served as controls.
For bilateral injections into the CPu, MSX-3 (MSX-2 phosphate diNa salt, [3-(3-hydroxypropyl)-8-(3-methoxystyryl)-7-methyl-1-propargylxanthine; Mu Èller et al., 1998 ], SCH23390 (Research Biochemicals Int., Koeln, Germany) and S(±)-sulpiride [(±)-5-(Aminosulphonyl)-N-(1-ethyl-2-pyrrodinylmethyl)-2-methoxy-benzamide] (Research Biochemicals Int., Koeln, Germany) were dissolved in 0.9% saline and adjusted to pH of 6.0±7.2. MSX-3 (7 mg) was administered 10 min, SCH23390 (10 mg) and sulpiride (15 mg) 20 min before the onset of behavioural testing in a volume of 1 mL in each hemisphere, respectively. The doses and the timing of injections were chosen to ensure a pronounced drug-induced motor effect Hauber & Lutz, 1999) . The doses of S(±)-sulpiride and SCH23390 were also chosen based on their ability to induced comparable degrees of catalepsy. For intracerebral injection, S(±)-sulpiride, but not raclopride, was used to block D 2 receptors as S(±)-sulpiride showed only little spread outside the infusion area (Ahlenius et al., 1990) . For systemic administration, raclopride, but not S(±)-sulpiride, was used to block D 2 receptors, because the cataleptic effects of S(±)-sulpiride had a delayed onset with this route of injection (Elliott et al., 1990) .
Intracerebral drug infusion
On injection days, the obturators were removed and injection cannulae, with an outer diameter of 0.45 mm, were lowered at the ®nal site of infusion and attached via polyethylene tubing to microliter syringes controlled by a microdrive pump (Kopf Instruments, Tujunga, CA, USA). Drugs and respective vehicles (1.0 mL) were delivered bilaterally at a rate of 0.5 mL/min. Injection cannulae were left in position for an additional 1 min after each infusion to allow for diffusion. Each rat remained in its home cage for an additional 5 min before catalepsy testing.
Catalepsy testing
The standard bar test was used to determine the intensity of catalepsy (e.g. Hoffman & Donovan, 1995) . Both forelegs of a rat were placed on a horizontal bar (diameter, 0.7 cm) 9 cm above the surface. The latency from paw placement until the ®rst complete removal of one paw from the support was measured (maximal test duration, 180 s) and termed here as descent latency. If the rat did not assume the position on the bar after three attempts, it received a descent latency of 0 s.
Histology
After completion of behavioural testing, animals were killed by an overdose of sodium pentobarbital (150 mg/kg, i.p.; Sigma-Aldrich, Seelze, Germany) to control for correct placement of cannulae. Brains were rapidly removed, ®xed in 10% formalin for 2.5 h and stored in 30% sucrose. Brain sections (20 mm) were cut with a cryostat (Reichert and Jung, Nussloch, Germany), mounted on coated slides and stained with Cresyl Violet. Cannulae placements were veri®ed with reference to the atlas of Paxinos & Watson (1986) . Only animals in which cannulae tip placements deviated less than 0.5 mm from target co-ordinates in the CPu were evaluated.
Data analysis
Results are expressed as means T standard error of the mean (SEM). Data were subjected to a nonparametric statistical analysis using a Mann±Whitney U-test (two-tailed) or a Kruskal±Wallis one way analysis of variance (ANOVA) on ranks followed by a multiple comparison procedure after Dunnett's method (equal sample sizes) or Dunn's method (unequal sample sizes). The level of statistical signi®cance (a-level) was set at P < 0.05. The SigmaStat (Vers. 2.0, Jandel, Hamburg, Germany) statistical package was used for all statistical computations.
Results
Effects of theophylline and CSC on catalepsy due to systemic D 2 receptor blockade Systemic blockade of D 2 receptors by raclopride (1.25 mg/kg, i.p.) produced prominent catalepsy which was reversed by systemic coadministration of the unselective A 1 /A 2 receptor antagonist theophylline. The anticataleptic effect of theophylline was statistically signi®cant after administration of 10 mg/kg (i.p.) (H = 7.78, P < 0.05; ANOVA followed by multiple comparisons after Dunnett's method), but not after administration of 5 mg/kg (i.p.) as shown Fig. 1A . Likewise, catalepsy induced by systemic administration of raclopride (1.25 mg/kg, i.p.) was signi®cantly antagonized by systemic coadministration of the selective A 2A receptor antagonist, CSC (5 mg/kg, i.p., P < 0.01, Mann±Whitney U-test; Fig. 1B) .
Effects of theophylline and CSC on catalepsy due to systemic D 1 receptor blockade Systemic blockade of D 1 receptors by SCH23390 (0.75 mg/kg, i.p.) produced prominent catalepsy which was reversed by systemic coadministration of theophylline (5, 10 mg/kg, i.p.), reaching signi®cance with the higher dose (H = 6.05, P < 0.05; ANOVA followed by multiple comparisons after Dunn's method) ( Fig. 2A) . Furthermore, catalepsy induced by systemic administration of SCH23390 (0.75 mg/kg, i.p.) was antagonized by systemic coadministration of CSC (5 mg/kg, i.p., P < 0.01, Mann±Whitney U-test) as depicted in Fig. 2B .
Effects of theophylline and CSC on catalepsy due to intra-CPu D 2 receptor blockade Intra-CPu blockade of D 2 receptors by S(±)-sulpiride (15 mg in 1 mL per side) produced prominent catalepsy which was reversed by systemic coadministration of the unselective A 1 /A 2 receptor antagonist, theophylline. The anticataleptic effect of theophylline was signi®cant after administration of 10 mg/kg (i.p.) (H = 7.68, P < 0.05; ANOVA followed by multiple comparisons after Dunn's method), but not after administration of 5 mg/kg (i.p.) as shown Fig. 3A . Likewise, catalepsy induced by intra-CPu infusion of S(±)-sulpiride was signi®cantly antagonized by systemic coadministration of the selective A 2A receptor antagonist, CSC (5 mg/kg, i.p., P < 0.01, Mann±Whitney U-test; Fig. 3B ).
Effects of theophylline and CSC on catalepsy due to intra-CPu D 1 receptor blockade Intra-CPu blockade of D 1 receptors by SCH23390 (10 mg in 1 mL per side) produced prominent catalepsy which was reversed by systemic coadministration of the unselective A 1 /A 2 antagonist, theophylline. The anticataleptic effect of theophylline was signi®cant after administration of 10 mg/kg (i.p.) (H = 8.22, P < 0.05; ANOVA followed by multiple comparisons after Dunn's method), but not after administration of 5 mg/kg (i.p.) as shown Fig. 4A . Catalepsy induced by intra-CPu infusion of SCH23390 was not antagonized signi®cantly by systemic coadministration of the selective A 2A receptor antagonist CSC (5 mg/kg, i.p., P > 0.05, Mann±Whitney U-test; Fig. 4B ). Effects of MSX-3 on catalepsy due to intra-CPu D 2 and D 1 receptor blockade As shown in Fig. 5 , intra-CPu blockade of D 2 receptors by S(±)-sulpiride (15 mg in 1 mL per side) produced strong catalepsy which was reversed by intra-CPu co-microinfusion of the selective A 2 receptor antagonist MSX-3 (P < 0.01, Mann±Whitney U-test). In addition, catalepsy after blockade of intra-CPu D 1 receptors by SCH23390 (10 mg in 1 mL per side) was reversed by intra-CPu coinfusion of the selective A 2 receptor antagonist MSX-3 (P < 0.03, Mann±Whitney U-test).
Histology
In all animals evaluated, cannulae tip placements deviated less than 0.5 mm from target co-ordinates in the CPu. The location of cannulae tips for all rats evaluated are represented in Fig. 6 .
Discussion
The main ®nding of the present study is that catalepsy due to a blockade of D 1 or D 2 receptors within the CPu can be reversed by a concomitant intra-CPu A 2A receptor blockade. These behavioural data provide direct evidence for the notion that the CPu is a critical neural substrate for the antagonistic control of motor activity by dopamine and adenosine.
In line with previous data (Casas et al., 1988; Kanda et al., 1994; Kafka & Corbett, 1996; Mandhane et al., 1997) , our results demonstrate that catalepsy, induced by a systemic or intra-CPu blockade of D 2 receptors, was potently reversed by systemic administration of the unselective A 1 /A 2 receptor antagonist, theophylline and the selective A 2A receptor antagonist, CSC. On the other hand, selective A 1 receptor antagonists did not alter catalepsy induced by systemic reserpine or haloperidol (Kanda et al., 1994; Mandhane et al., 1997) . Hence, these ®ndings consistently support the general notion that A 2A receptors play a prominent role in anticataleptic responses (Ferre Â et al., 1991; Kanda et al., 1994; Hauber et al., 1998; Kanda et al., 1998; Shiozaki et al., 1999) .
Our data further reveal that catalepsy, due to systemic or intra-CPu blockade of D 1 receptors, was counteracted by systemic administration of the unselective A 1 /A 2 receptor antagonist theophylline. Likewise, the selective A 2A receptor antagonist CSC reversed catalepsy induced by a systemic D 1 receptor blockade. These data point to the view that a blockade of A 2A receptors might primarily account for the anticataleptic effects of theophylline and CSC in these experiments with a D 1 receptor blockade. However, for unknown reasons, CSC had only minimal effects on catalepsy induced by a blockade of intra-CPu D 1 receptors. This negative result suggests that the particular interaction between CSC and intra-CPu SCH23390 involves yet unidenti®ed mechanisms that might prevent the anticataleptic actions of CSC seen in our other experiments. In view of the high densities of D 1 , D 2 (Rich®eld et al., 1987) and A 2A (Svenningsson et al., 1999) receptors in the CPu, it reasonable to assume that this structure is the main neural substrate to mediate the antagonistic motor effects induced by a systemic blockade of D 1 and D 2 receptors vs. A 2A receptors. However, this hypothesis is limited because D 1 and D 2 receptors in basal ganglia nuclei downstream of the CPu, i.e. extrastriatal basal ganglia nuclei, play a crucial role in catalepsy as well (Costall et al., 1972; Hauber, 1998a; Hauber & Lutz, 1999) . Hence, dopamine hypofunction in extrastriatal basal ganglia nuclei also contributes to the expression of catalepsy following systemic manipulations of the dopaminergic system (see Hauber, 1998b) . Furthermore, A 2A receptors are expressed in moderate to low densities in extrastriatal basal ganglia nuclei (Rosin et al., 1998) and interact with D 2 receptors in these structures (May®eld et al., 1993; May®eld et al., 1996; Le Moine et al., 1997) . Given the extrastriatal A 2A receptor expression, a number of possible mechanisms could explain how D 1 and D 2 receptor-dependent catalepsy may be reversed by a concomitant A 2A receptor blockade. The ®rst part of this study, as well as other work (e.g. Kanda et al. 2000; Kanda et al., 1994; Kanda et al., 1998) reporting anticataleptic effects of an A 2A receptor blockade in animals with dopamine hypofunction, used systemic administration of selective antagonists and, therefore, do not allow direct characterization of the neural substrates mediating the behavioural effects. Thus, in the second part of the present study, we used a novel water-soluble A 2A receptor antagonist, MSX-3 (suitable for intracerebral microinfusion) and revealed that blockade of A 2A receptors in the CPu potently reversed catalepsy induced by intra-CPu blockade of D 1 as well as D 2 receptors. These ®ndings con®rm and extend our previous study and provide strong support for the notion that the CPu is a major neural substrate for the antagonistic motor effects mediated by dopamine via D 1 /D 2 receptors and adenosine via A 2A receptors. However, as noted above, there are additional basal ganglia structures downstream from the CPu which might contribute to the anticataleptic effects of systemically administered A 2A receptor antagonists.
The MSX-3-induced reversal of D 2 receptor-mediated catalepsy might be brought about by functionally antagonistic effects of a blockade of A 2A and D 2 receptors coexpressed on striatopallidal neurons. These antagonistic effects might involve the well-established intra-membrane interactions of A 2A and D 2 receptors (Fuxe et al., 1998; Zahniser et al. 2000) as well as mechanisms independent of direct receptor±receptor interactions (Richardson et al., 1997; Aoyama et al. 2000) . In addition, it can not be excluded that striatal GABAergic and cholinergic interneurons which express very low levels of A 2A receptors (for example, see Richardson et al., 1997) contribute to this effect. The intra-CPu blockade of A 2A receptors by MSX-3 also reversed D 1 receptor-mediated catalepsy. A 2A and D 1 receptors are anatomically separated and functional studies revealed that stimulation of both receptors increased intracellular cAMP in nonoverlapping neuronal populations, presumably striatonigral and striatopallidal neurons (see Svenningsson et al., 1999) . Because of the segregation of A 2A and D 1 receptors, the MSX-3 induced reversal of D 1 receptor-mediated catalepsy might be explained by functionally antagonistic effects of striatopallidal and striatonigral pathways in the output structures. Such network effects within the basal ganglia have been proposed to underlie the A 2A receptor antagonist-induced potentiation of D 1 receptor-mediated rotation (Pinna et al., 1996; Pollack & Fink, 1996; Fenu et al., 1997; also, see Ferre Â et al., 1997) .
Our FIG. 6. The shaded areas represent the regions in the CPu where cannulae tips for all rats used for data analysis were located. The plate is an adaptation from the atlas of Paxinos & Watson (1986) . The number beside the plate corresponds to millimeters anterior to bregma.
receptor stimulation reversed D 1 as well as D 2 receptor-mediated rotation in rats with unilateral nigrostriatal lesions (Jiang et al., 1993; Morelli et al., 1994) . On the other hand, there is recent evidence that an A 2A receptor antagonism did not potentiate D 1 receptor-mediated turning as strong as D 2 receptor-mediated turning (Pinna et al., 1996; Pollack & Fink, 1996; Fenu et al., 1997; Stromberg et al. 2000) . This difference has been suggested to indicate that interactions between A 2A and D 1 receptors at the circuit level are less effective (Stromberg et al. 2000) or, alternatively, additional mechanisms between these receptors might account for this difference . Our results with systemic and intra-CPu drug administration provide no evidence that D 1 and D 2 receptormediated catalepsy was differentially reversed by an A 2A receptor blockade. However, the data do not allow us to conclude that an A 2A receptor blockade reversed D 1 and D 2 receptor-mediated catalepsy to the same extent, because the degrees of D 1 and D 2 receptor-mediated catalepsy were variable throughout our experiments and only a limited dose±response range of A 2A and dopamine receptor antagonists was tested. Nevertheless, the data imply that striatal A 2A receptors are tonically activated and that their blockade produced changes in the activity of striatopallidal neurons strong enough to compensate for both D 1 and D 2 receptor-mediated hypokinesia. The underlying antagonistic mechanisms are probably different in that they are located either at a common neuronal substrate (A 2A ±D 2 receptors) or at the network level (A 2A ±D 1 receptors).
In summary, using intracerebral co-microinfusions the present study provides, to the best of our knowledge, the ®rst direct evidence that the CPu is a critical neural substrate which mediates the antagonistic motor effects of an A 2A receptor blockade and a D 1 or D 2 receptor blockade. The data add further support to the notion that A 2A receptor antagonists may be useful therapeutics for the treatment of Parkinson's disease (Richardson et al., 1997; Mally & Stone, 1998) .
